Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
Lars Erik KristensenMauro KeisermanKim A PappLeslie McCaslandDouglas WhiteKyle CarterRalph LippeHuzefa PhotowalaLeonidas DrogarisAhmed M SolimanMichael ChenByron PadillaFrank BehrensPublished in: Rheumatology and therapy (2024)
ClinicalTrials.gov identifier, NCT03675308.